A Long-term Safety Study of Once-daily Travatan
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Long-term Safety Study of Once-daily TRAVATAN|
- Mean Intraocular Pressure [ Time Frame: At 5 years. ] [ Designated as safety issue: Yes ]
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken.
All IOP measurements were performed with a Goldmann applanation tonometer.
|Study Start Date:||January 2006|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Travoprost (0.004%) 1 drop each eye once daily
Please refer to this study by its ClinicalTrials.gov identifier: NCT00051168
|United States, Texas|
|Fort Worth, Texas, United States|